A photo of LaQuita Jones.

Member, Division of Oncology

513-636-4505

Board Certified

My Biography & Research

Biography

I first developed a sincere interest in pediatric oncology during a medical school rotation, where I witnessed the resilience of children with cancer. Thereafter, my desire to impact therapeutic innovation for the field of pediatric oncology drove me to understand the underlying mechanisms behind resistance to targeted therapies and novel targeted therapy combinations in the treatment of acute myeloid leukemia (AML).

Exposure to various patients during my residency and fellowship increased my interest in pediatric AML specifically. Having those clinical experiences made me acutely aware of the need to continue improving therapies for AML.

I am board certified in pediatrics and pediatric hematology/oncology, and I completed my fellowship in pediatric hematology/oncology in 2018.

So far during my career, I’ve been honored to receive:

  • St. Baldrick's Fellowship Award (2017 to 2020) from the St. Baldrick's Foundation, which funds childhood cancer research
  • CT2 Scholar (2019 to 2020) funded by the Clinical & Translational Sciences Awards Program (CTSA)
  • KL2 Award (2020) funded by the CTSA and National Institutes of Health (NIH)

Clinical Interests

Pediatric leukemia and lymphoma

Research Interests

Targeted therapeutics for FLT3 mutant AML and resistance patterns in AML

Clinical Divisions

Cancer and Blood Diseases

Research Divisions

Oncology

My Education

DO: Ohio University Heritage College of Osteopathic Medicine, Athens, OH, 2012.

Residency: Pediatrics, Nationwide Children's Hospital, Columbus, OH, 2015.

Fellowship: Pediatric Hematology and Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2018.

Certification: Pediatrics.

My Publications

Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. Jones, LM; Melgar, K; Bolanos, L; Hueneman, K; Walker, MM; Jiang, J; Wilson, KM; Zhang, X; Shen, J; Jiang, F; et al. Journal of Clinical Investigation. 2020; 130:2017-2023.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al. Science Translational Medicine. 2019; 11:eaaw8828-eaaw8828.

Successful management of concurrent acquired hemophilia A and a lupus anticoagulant in a pediatric hematopoietic stem cell transplant patient. Jones, L; Dandoy, C; Jodele, S; Myers, KC; Luchtman-Jones, L; Quinn, CT; Mullins, E; El-Bietar, J. Bone Marrow Transplantation. 2018; 53:487-489.